Sign in

You're signed outSign in or to get full access.

Ashley Aloupis

Research Analyst at Piper Sandler

Ashley Aloupis is an Equity Research Associate at Piper Sandler, specializing in equity research within the finance sector. She contributes to analysis and coverage in this field, though specific companies covered and detailed performance metrics such as success rates or returns are not publicly detailed in available sources. Aloupis joined Piper Sandler in July 2023, marking the start of her tenure at the firm with prior experience in finance not specified in current records. Her professional credentials include relevant finance qualifications typical for an equity research role, such as potential FINRA registrations, though exact licenses are unconfirmed.

Ashley Aloupis's questions to RIGEL PHARMACEUTICALS (RIGL) leadership

Question · Q4 2025

Ashley Aloupis, on behalf of Alexandre Brasil, asked about the strategic rationale for exploring R289 in a less heavily pretreated, post-ESA or treatment-naive lower-risk MDS population now, rather than waiting for a registrational trial, and what specific benefit (response rates, durability) Rigel aims to show in this earlier-line population.

Answer

Lisa Rojkjaer (EVP and Chief Medical Officer, Rigel Pharmaceuticals) explained that the current study population is heavily pretreated, and moving to an earlier line (post-ESA or ESA-ineligible) aligns with how other agents like luspatercept and imetelstat generated their data, with an expectation of even better activity. Raul Rodriguez (President and CEO, Rigel Pharmaceuticals) added that current approved products have limitations (38-40% response rates for luspatercept/imetelstat, 18-20% for HMAs), and R289's different mechanism, showing 33% response in very refractory patients at doses >=500mg, suggests potential for broader and improved benefit in earlier lines.

Ask follow-up questions

Fintool

Fintool can predict RIGEL PHARMACEUTICALS logo RIGL's earnings beat/miss a week before the call